Can the treatment of vascular risk factors slow cognitive decline in Alzheimer's disease patients?

Journal of Alzheimer's Disease

Volumn 32, Issue 3, 2012, Pages 765-772

  Richard, Florence ^a,b,c,d   Pasquier, Florence ^b,c,d  

^a INSTITUT PASTEUR DE LILLE   (France)

^b UNIV LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d Excellence Laboratory DISTALZ   (France)

Author keywords

Alzheimer's disease; cerebrovascular disorders; control; disease progression; vascular risk factor

Indexed keywords

ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; ROSIGLITAZONE; SIMVASTATIN;

ALZHEIMER DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DIABETES MELLITUS; DISEASE COURSE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 84872258636     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-121012     Document Type: Review

References (88)

1. WHO. Dementia - A public health priority. http://www.who. int/mental health/publications/dementia report 2012/en/.
2. Knopman DS, Roberts R (2010) Vascular risk factors: Imaging and neuropathologic correlates. J Alzheimers Dis 20, 699-709.
3. Viswanathan A, Rocca WA, Tzourio C (2009) Vascular risk factors and dementia: How to move forward? Neurology 72, 368-374.
4. Henon H, Durieu I, Guerouaou D, Lebert F, Pasquier F, Leys D (2001) Poststroke dementia: Incidence and relationship to prestroke cognitive decline. Neurology 57, 1216-1222. (Pubitemid 32947379)
5. Iadecola C (2010) The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol 120, 287-296.
6. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR (1997) Brain infarction and the clinical expression of alzheimer disease The Nun Study. JAMA 277, 813-817. (Pubitemid 27111317)
7. Dietschy JM (2009) Central nervous system: Cholesterol turnover, brain development and neurodegeneration. Biol Chem 390, 287-293.
8. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van DuijnCM(1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and alzheimer disease.Ameta-Analysis. APOE and alzheimer Disease Meta Analysis Consortium. JAMA 278, 1349-1356.
9. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC (2002) Apolipoprotein E polymorphism and cardiovascular disease: A HuGE review. Am J Epidemiol 155, 487-495. (Pubitemid 34208040)
10. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, Pappolla MA (2000) Hypercholesterolemia accelerates the alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7, 321-331.
11. Shie FS, Jin LW, Cook DG, Leverenz JB, LeBoeuf RC (2002) Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. Neuroreport 13, 455-459. (Pubitemid 34293189)
12. Boimel M, Grigoriadis N, Lourbopoulos A, Touloumi O, Rosenmann D, Abramsky O, Rosenmann H (2009) Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. J Neuropathol Exp Neurol 68, 314-325.
13. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T (2001) Simvastatin strongly reduces levels of alzheimer's disease beta-Amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A 98, 5856-5861. (Pubitemid 32435732)
14. Li G, Larson EB, Sonnen JA, Shofer JB, Petrie EC, Schantz A, Peskind ER, Raskind MA, Breitner JC, Montine TJ (2007) Statin therapy is associated with reduced neuropathologic changes of alzheimer disease. Neurology 69, 878-885. (Pubitemid 47329587)
15. Ancelin ML, Carriere I, Barberger-Gateau P, Auriacombe S, Rouaud O, Fourlanos S, Berr C, Dupuy AM, RitchieK(2012) Lipid lowering agents, cognitive decline, and dementia: The Three-City Study. J Alzheimers Dis 30, 629-637.
16. Arvanitakis Z, Schneider JA,Wilson RS, Bienias JL,Kelly JF, Evans DA, Bennett DA (2008) Statins, incident alzheimer disease, change in cognitive function, and neuropathology. Neurology 70, 1795-1802. (Pubitemid 351653958)
17. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM (2009) Statins are associated with a reduced risk of alzheimer disease regardless of lipophilicity The rotterdam study. J Neurol Neurosurg Psychiatry 80, 13-17.
18. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A (2001) Midlife vascular risk factors and alzheimer's disease in later life: Longitudinal, population based study. BMJ 322, 1447-1451. (Pubitemid 32575406)
19. Zhou B, Teramukai S, Fukushima M (2007) Prevention and treatment of dementia or alzheimer's disease by statins: A meta-Analysis. Dement Geriatr Cogn Disord 23, 194-201. (Pubitemid 46333787)
20. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-Risk individuals: A randomised placebo-controlled trial. Lancet 360, 7-22.
21. Shepherd J, Blauw GJ, MurphyMB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 360, 1623-1630. (Pubitemid 35379733)
22. Helzner EP, Luchsinger JA, Scarmeas N, Cosentino S, Brickman AM, Glymour MM, Stern Y (2009) Contribution of vascular risk factors to the progression in alzheimer disease. Arch Neurol 66, 343-348.
23. Musicco M, Palmer K, Salamone G, Lupo F, Perri R, Mosti S, Spalletta G, di Iulio F, Pettenati C, Cravello L, Caltagirone C (2009) Predictors of progression of cognitive decline in alzheimer's disease: The role of vascular and sociodemographic factors. J Neurol 256, 1288-1295.
24. Sakurai H, Hanyu H, Sato T, Kanetaka H, Shimizu S, Hirao K, Kikukawa M, Iwamoto T (2011) Vascular risk factors and progression in alzheimer's disease. Geriatr Gerontol Int 11, 211-214.
25. Evans RM, Hui S, Perkins A, Lahiri DK, Poirier J, FarlowMR (2004) Cholesterol and APOE genotype interact to influence alzheimer disease progression. Neurology 62, 1869-1871. (Pubitemid 38661755)
26. Li J, Wang YJ, Zhang M, Xu ZQ, Gao CY, Fang CQ, Yan JC, Zhou HD (2011) Vascular risk factors promote conversion from mild cognitive impairment to alzheimer disease. Neurology 76, 1485-1491.
27. Hajjar I, Schumpert J, Hirth V,Wieland D, Eleazer GP (2002) The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci 57, M414-M418. (Pubitemid 34733805)
28. Masse I, Bordet R, Deplanque D, Al Khedr A, Richard F, Libersa C, Pasquier F (2005) Lipid lowering agents are associated with a slower cognitive decline in alzheimer's disease. J Neurol Neurosurg Psychiatry 76, 1624-1629. (Pubitemid 41697623)
29. Locatelli S, Lutjohann D, Schmidt HH, Otto C, Beisiegel U, von Bergmann K (2002) Reduction of plasma 24Shydroxycholesterol (cerebrosterol) levels using high-Dosage simvastatin in patients with hypercholesterolemia: Evidence that simvastatin affects cholesterol metabolism in the human brain. Arch Neurol 59, 213-216. (Pubitemid 34240936)
30. Simons M, Schwarzler F, Lutjohann D, von Bergmann K, Beyreuther K, Dichgans J, Wormstall H, Hartmann T, Schulz JB (2002) Treatment with simvastatin in normocholesterolemic patients with alzheimer's disease: A 26-week randomized, placebo-controlled, double-Blind trial. Ann Neurol 52, 346-350. (Pubitemid 35001502)
31. Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, Wasser D, Johnson-Traver S, Lochhead J, Ziolwolski C (2005) Atorvastatin for the treatment of mild to moderate alzheimer disease: Preliminary results. Arch Neurol 62, 753-757. (Pubitemid 40656090)
32. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A (2010) Randomized controlled trial of atorvastatin in mild to moderate alzheimer disease: LEADe. Neurology 74, 956-964.
33. Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, Aisen PS (2011) A randomized, double-Blind, placebo-controlled trial of simvastatin to treat alzheimer disease. Neurology 77, 556-563.
34. Papassotiropoulos A, Lutjohann D, Bagli M, Locatelli S, Jessen F, Rao ML, Maier W, Bjorkhem I, von Bergmann K, Heun R (2000) Plasma 24S- hydroxycholesterol: A peripheral indicator of neuronal degeneration and potential state marker for alzheimer's disease. Neuroreport 11, 1959-1962.
35. de la Monte SM (2009) Insulin resistance and alzheimer's disease. BMB Rep 42, 475-481.
36. Jolivalt CG, Hurford R, Lee CA, Dumaop W, Rockenstein E, Masliah E (2010) Type 1 diabetes exaggerates features of alzheimer's disease in APP transgenic mice. Exp Neurol 223, 422-431.
37. Ke YD, Delerue F, Gladbach A, Gotz J, Ittner LM (2009) Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of alzheimer's disease. Plos One 19, e7917.
38. Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, Kurinami H, Shinohara M, Rakugi H, Morishita R (2010) Diabetes-Accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A 107, 7036-7041.
39. McClean PL, ParthsarathyV, Faivre E, HolscherC(2011) The diabetes drug liraglutide prevents degenerative processes in a mouse model of alzheimer's disease. J Neurosci 31, 65876594.
40. Rodriguez-Rivera J, Denner L, Dineley KT (2011) Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-Regulatory status. Behav Brain Res 216, 255-261.
41. Pasquier F, Boulogne A, Leys D, Fontaine P (2006) Diabetes mellitus and dementia. Diabetes Metab 32, 403-414. (Pubitemid 44841847)
42. van Elderen SG, de Roos A, de Craen AJ, Westendorp RG, Blauw GJ, Jukema JW, Bollen EL, Middelkoop HA, van Buchem MA, van der GJ (2010) Progression of brain atrophy and cognitive decline in diabetes mellitus:A3-year follow-up. Neurology 75, 997-1002.
43. Craft S, Peskind E, SchwartzMW, Schellenberg GD, Raskind M, Porte D Jr (1998) Cerebrospinal fluid and plasma insulin levels in alzheimer's disease: Relationship to severity of dementia and apolipoprotein E genotype. Neurology 50, 164168.
44. Gil-Bea FJ, Solas M, Solomon A, Mugueta C, Winblad B, Kivipelto M, Ramirez MJ, Cedazo-Minguez A (2010) Insulin levels are decreased in the cerebrospinal fluid of women with prodomal alzheimer's disease. J Alzheimers Dis 22, 405-413.
45. Launer LJ, Miller ME, Williamson JD, Lazar RM, Gerstein HC, Murray AM, SullivanM, Horowitz KR, Ding J, Marcovina S, Lovato LC, Lovato J, Margolis KL, O'Connor P, Lipkin EW, Hirsch J, Coker L, Maldjian J, Sunshine JL, Truwit C, Davatzikos C, Bryan RN (2011) Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): A randomised open-Label substudy. Lancet Neurol 10, 969-977.
46. Regan C, Katona C, Walker Z, Hooper J, Donovan J, Livingston G (2006) Relationship of vascular risk to the progression of alzheimer disease. Neurology 67, 1357-1362. (Pubitemid 44632057)
47. Boksay I, Boksay E, Reisberg B, Torossian C, Krishnamurthy M (2005) alzheimer's disease and medical disease conditions: A prospective cohort study. J Am Geriatr Soc 53, 2235-2236. (Pubitemid 43001215)
48. Mielke MM, Rosenberg PB, Tschanz J, Cook L, Corcoran C, Hayden KM, Norton M, Rabins PV, Green RC, WelshBohmer KA, Breitner JC, Munger R, Lyketsos CG (2007) Vascular factors predict rate of progression in alzheimer disease. Neurology 69, 1850-1858. (Pubitemid 350071146)
49. Sanz C, Andrieu S, Sinclair A, Hanaire H, Vellas B (2009) Diabetes is associated with a slower rate of cognitive decline in alzheimer disease. Neurology 73, 1359-1366.
50. Plastino M, Fava A, Pirritano D, Cotronei P, Sacco N, Sperli T, Spano A, Gallo D, Mungari P, Consoli D, Bosco D (2010) Effects of insulinic therapy on cognitive impairment in patients with alzheimer disease and diabetes mellitus type-2. J Neurol Sci 288, 112-116.
51. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD (2006) Efficacy of rosiglitazone in a genetically defined population with mild-To-moderate alzheimer's disease. Pharmacogenomics J 6, 246-254. (Pubitemid 44137951)
52. Harrington C, Sawchak S, Chiang C, Davies J, Donovan C, Saunders AM, Irizarry M, Jeter B, Zvartau-Hind M, van Dyck CH, Gold M (2011) Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-To-moderate alzheimer's disease: Two phase 3 studies. Curr alzheimer Res 8, 592606.
53. Tzimopoulou S, Cunningham VJ, Nichols TE, Searle G, Bird NP, Mistry P, Dixon IJ, Hallett WA, Whitcher B, Brown AP, Zvartau-Hind M, Lotay N, Lai RY, Castiglia M, Jeter B, Matthews JC, Chen K, Bandy D, Reiman EM, Gold M, Rabiner EA, Matthews PM (2010) A multi-center randomized proof-of-concept clinical trial applying [(1)F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate alzheimer's disease. J Alzheimers Dis 22, 1241-1256.
54. Hanyu H, Sato T, Kiuchi A, Sakurai H, Iwamoto T (2009) Pioglitazone improved cognition in a pilot study on patients with alzheimer's disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr Soc 57, 177-179.
55. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T (2011) Efficacy of PPAR-gamma agonist pioglitazone in mild alzheimer disease. Neurobiol Aging 32, 1626-1633.
56. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B (2012) Intranasal insulin therapy for alzheimer disease and amnestic mild cognitive impairment:Apilot clinical trial. Arch Neurol 69, 29-38.
57. Reger MA,Watson GS, Green PS,Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S (2008) Intranasal insulin improves cognition and modulates beta-Amyloid in early AD. Neurology 70, 440-448.
58. Qiu C, Winblad B, Fratiglioni L (2005) The age-Dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 4, 487-499. (Pubitemid 40982459)
59. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Oden A, Svanborg A (1996) 15-year longitudinal study of blood pressure and dementia. Lancet 347, 1141-1145. (Pubitemid 126512042)
60. den Heijer T, Launer LJ, Prins ND, van Dijk EJ, Vermeer SE, Hofman A, Koudstaal PJ, Breteler MM (2005) Association between blood pressure, white matter lesions, and atrophy of the medial temporal lobe. Neurology 64, 263-267.
61. Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, Nelson J, Davis DG, Hardman J, Foley DJ, Launer LJ (2000) Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: The HAAS. Honolulu-Asia aging Study. Neurobiol Aging 21, 57-62. (Pubitemid 30224786)
62. Hoffman LB, Schmeidler J, Lesser GT, Beeri MS, Purohit DP, Grossman HT, Haroutunian V (2009) Less alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology 72, 1720-1726.
63. Takeda S, Sato N, Takeuchi D, Kurinami H, Shinohara M, Niisato K, Kano M, Ogihara T, Rakugi H, Morishita R (2009) Angiotensin receptor blocker prevented beta-Amyloidinduced cognitive impairment associated with recovery of neurovascular coupling. Hypertension 54, 1345-1352.
64. Tsukuda K, Mogi M, Iwanami J, Min LJ, Sakata A, Jing F, Iwai M, Horiuchi M (2009) Cognitive deficit in amyloid-Beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-Activated receptor-gamma activation. Hypertension 54, 782-787.
65. Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, Tschanz JT, Mayer LS,Welsh-Bohmer KA, Breitner JC (2006) Antihypertensive medication use and incident alzheimer disease: The Cache County Study. Arch Neurol 63, 686-692.
66. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B (2010) Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: Prospective cohort analysis. BMJ 340, b5465.
67. Sink KM, Leng X, Williamson J, Kritchevsky SB, Yaffe K, Kuller L, Yasar S, Atkinson H, Robbins M, Psaty B, Goff DC Jr (2009) Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: Results from the Cardiovascular Health Study. Arch Intern Med 169, 1195-1202.
68. Amenta F, Mignini F, Rabbia F, Tomassoni D,Veglio F (2002) Protective effect of anti-hypertensive treatment on cognitive function in essential hypertension: Analysis of published clinical data. J Neurol Sci 203-204, 147-151. (Pubitemid 35287391)
69. Anderson C, Teo K, Gao P, Arima H, Dans A, Unger T, Commerford P, Dyal L, Schumacher H, Pogue J, Paolasso E, Holwerda N, Chazova I, Binbrek A, Young J, Yusuf S (2011) Renin-Angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: Analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol 10, 43-53.
70. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Birkenhager WH (2002) The prevention of dementia with antihypertensive treatment: New evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 162, 2046-2052. (Pubitemid 35168212)
71. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, Waldman A, Walton I, Poulter R, Ma S, Comsa M, Burch L, Fletcher A, Bulpitt C (2008) Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): A double-Blind, placebo controlled trial. Lancet Neurol 7, 683-689.
72. Prince MJ, Bird AS, Blizard RA, Mann AH (1996) Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. BMJ 312, 801-805. (Pubitemid 26099297)
73. Starr JM, Whalley LJ, Deary IJ (1996) The effects of antihypertensive treatment on cognitive function: Results from the HOPE study. J Am Geriatr Soc 44, 411-415. (Pubitemid 26115555)
74. Endres M, Heuschmann PU, Laufs U, HakimAM(2011) Primary prevention of stroke: Blood pressure, lipids, and heart failure. Eur Heart J 32, 545-552.
75. Godin O, Tzourio C, Maillard P, Mazoyer B, Dufouil C (2011) Antihypertensive treatment and change in blood pressure are associated with the progression of white matter lesion volumes: The Three-City (3C)-Dijon Magnetic Resonance Imaging Study. Circulation 123, 266-273.
76. Bellew KM, Pigeon JG, Stang PE, Fleischman W, Gardner RM, Baker WW (2004) Hypertension and the rate of cognitive decline in patients with dementia of the alzheimer type. alzheimer Dis Assoc Disord 18, 208-213. (Pubitemid 40076150)
77. Razay G, Williams J, King E, Smith AD, Wilcock G (2009) Blood pressure, dementia and alzheimer's disease: The OPTIMA longitudinal study. Dement Geriatr Cogn Disord 28, 70-74.
78. Duron E, Rigaud AS, Dubail D, Mehrabian S, Latour F, Seux ML, Hanon O (2009) Effects of antihypertensive therapy on cognitive decline in alzheimer's disease. Am J Hypertens 22, 1020-1024.
79. Guo Z, Fratiglioni L, Zhu L, Fastbom J,Winblad B, Viitanen M (1999) Occurrence and progression of dementia in a community population aged 75 years and older: Relationship of antihypertensive medication use. Arch Neurol 56, 991-996. (Pubitemid 29374817)
80. Hajjar IM, Keown M, Lewis P, Almor A (2008) Angiotensin converting enzyme inhibitors and cognitive and functional decline in patients with alzheimer's disease:Anobservational study. Am J Alzheimers Dis Other Demen 23, 77-83.
81. Rozzini L, Vicini CB, Trabucchi M, Padovani A (2008) Antihypertensive medications influence the rate of conversion from mild cognitive impairment to alzheimer disease. Arch Neurol 65, 993-994. (Pubitemid 352008496)
82. Ohrui T, Tomita N, Sato-Nakagawa T, Matsui T, Maruyama M, Niwa K, Arai H, Sasaki H (2004) Effects of brainpenetratingACEinhibitors on alzheimer disease progression. Neurology 63, 1324-1325. (Pubitemid 39350046)
83. Abellan vK, Rolland Y, Nourhashemi F, Coley N, Andrieu S, Vellas B (2009) Cardiovascular disease risk factors and progression of alzheimer's disease. Dement Geriatr Cogn Disord 27, 240-246.
84. Goldstein FC, Ashley AV, Endeshaw YW, Hanfelt J, Lah JJ, Levey AI (2008) Effects of hypertension and hypercholesterolemia on cognitive functioning in patients with alzheimer disease. alzheimer Dis Assoc Disord 22, 336-342.
85. Kume K, Hanyu H, Sato T, Hirao K, Shimizu S, Kanetaka H, Sakurai H, Iwamoto T (2011) Vascular risk factors are associated with faster decline of alzheimer disease: A longitudinal SPECT study. J Neurol 258, 1295-1303.
86. Deschaintre Y, Richard F, Leys D, Pasquier F (2009) Treatment of vascular risk factors is associated with slower decline in alzheimer disease. Neurology 73, 674-680.
87. Richard E, Kuiper R, Dijkgraaf MG, Van Gool WA (2009) Vascular care in patients with alzheimer's disease with cerebrovascular lesions-A randomized clinical trial. J Am Geriatr Soc 57, 797-805.
88. Richard E, Gouw AA, Scheltens P, Van Gool WA (2010) Vascular care in patients with alzheimer disease with cerebrovascular lesions slows progression of white matter lesions on MRI: The evaluation of vascular care in alzheimer's disease (EVA) study. Stroke 41, 554-556.